GFM
ALNY icon

GF Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

GF Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.96M Sell
29,770
-271
-0.9% -$81.7K 0.11% 111
2026
Q1 		$9.94M Sell
30,041
-421
-1% -$143K 0.17% 93
2025
Q4 		$12.1M Buy
30,462
+27,665
+989% +$12.2M 0.21% 85
2025
Q3 		$1.28M Sell
2,797
-505
-15% -$206K 0.02% 185
2025
Q2 		$1.08M Hold
3,302
– – 0.02% 207
2025
Q1 		$892K Buy
3,302
+594
+22% +$153K 0.02% 210
2024
Q4 		$637K Buy
+2,708
New +$712K 0.01% 215

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's ALNY Position: Q2 2026 in Review

GF Fund Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.9% in Q2 2026, selling an estimated $81.7K and leaving 29,770 shares worth $8.96M. The position accounts for 0.11% of the portfolio, ranked #111.

GF Fund Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $12.1M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • GF Fund Management held 29,770 shares of Alnylam Pharmaceuticals worth $8.96M as of Q2 2026.
  • GF Fund Management sold 271 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $81.7K.
  • Alnylam Pharmaceuticals made up 0.11% of GF Fund Management's portfolio in Q2 2026, its #111 holding.
  • GF Fund Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Alnylam Pharmaceuticals position peaked at $12.1M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.